No Data
No Data
Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up
Express News | Sonnet’s Son-1010 Demonstrates a Strong Safety Profile in Combination With Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination With Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Sonnet Announces Release of Corporate Update Video
Sonnet BioTherapeutics Approves Promotion of Stephen McAndrew to Pres and Chief Business Officer >SONN
Express News | Sonnet Biotherapeutics Holdings - Board Has Unanimously Approved Appointment of Raghu Rao as Interim CEO